BioCentury
ARTICLE | Clinical News

Biogen, AC Immune swing on AD readouts

December 10, 2016 2:03 AM UTC

Biogen Inc. (NASDAQ:BIIB) shares seesawed Thursday and Friday, propelled upward by data showing that aducanumab (BIIB037) cleared amyloid plaques and improved cognition in an exploratory analysis of a Phase Ib study to treat Alzheimer's disease, but then tempered by safety concerns after the data were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting.

Investors' views of Biogen's data also were affected by a separate presentation late Thursday showing that beta amyloid-binding antibody solanezumab (LY2062430) from Eli Lilly and Co. (NYSE:LLY) failed to clear amyloid plaques in the Phase III EXPEDITION3 trial. Last month, Lilly said it would abandon solanezumab after it missed EXPEDITION3's primary endpoint, which measured cognitive decline. However, data presented Thursday evening showed the mAb did lead to a significant improvement in Clinical Dementia Rating-Sum of Boxes (CDR-SB) (p=0.004), the same endpoint Biogen is using in its ongoing Phase III study of aducanumab (see BioCentury Extra, Nov. 23). ...

BCIQ Company Profiles

AstraZeneca plc

Biogen Inc.

BCIQ Target Profiles

Beta amyloid